US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that affects the eye into late-stage ...

Shares of Aura Biosciences AURA gained 7.9% on Sept ... a layer of blood vessels and connective tissue between the sclera (white of the eye) and retina. It is the most common primary intraocular ...

is a prescription drug used to treat epilepsy and help prevent migraine headaches. It can cause side effects that range from mild to serious. Examples include hair loss and eye problems.